MindMaze Therapeutics Holding SA
https://www.mindmazetherapeutics.com
MindMaze Therapeutics Holding SA is a Swiss-based commercial-stage company focused on digital neurotherapeutics, dedicated to developing and commercializing digital treatments for neurological diseases and brain disorders. The company's mission is to accelerate the brain's ability to recover, learn, and adapt. Headquartered in Geneva, Switzerland, MindMaze Therapeutics integrates advanced software, proprietary sensors, and AI-driven data analytics to provide a continuum of care for patients.
The company's portfolio of FDA-listed and CE-marked products includes solutions for in-clinic and home-based neurorehabilitation. Key offerings such as the MindPod system, MindMotion GO, and the recently launched MindMotion Lite, a tablet-based solution, aim to provide personalized, intensive neurorehabilitation. MindMaze Therapeutics addresses a range of neurological conditions, including stroke, Parkinson's disease, traumatic brain injury, and age-related cognitive decline.
MindMaze Therapeutics Holding SA was established in December 2025 through the business combination of RELIEF THERAPEUTICS Holding SA and NeuroX Group SA. The company recently secured up to CHF 4 million in investment commitments to support the broader commercial deployment of its neurotherapeutics platform and expand access to home-based rehabilitation. Led by CEO Zach Henderson, MindMaze Therapeutics is positioned as a global leader in scalable precision neurotherapeutics, aiming to redefine neurological care.
Latest updates
